Earnings Call – Q1 - FY25 January 7, 2025 1 Safe Harbor Statement Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "expect," and "anticipate" mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors ...

Core Viewpoint - Simulations Plus reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share, but showing an increase from $0.10 per share a year ago, indicating a -5.56% earnings surprise [1] Financial Performance - The company posted revenues of $18.92 million for the quarter ended November 2024, surpassing the Zacks Consensus Estimate by 1.25%, and up from $14.5 million year-over-year [2] - Over the last four quarters, Simulations Plus has exceeded consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Simulations Plus shares have increased approximately 4.3% since the beginning of the year, outperforming the S&P 500's gain of 1.6% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.28 for the coming quarter and $1.11 for the current fiscal year, alongside revenues of $23.46 million and $90.87 million respectively [7] - The estimate revisions trend for Simulations Plus is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Computer - Software industry, to which Simulations Plus belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, indicating potential challenges ahead [8] - Another company in the same industry, PTC Inc., is expected to report quarterly earnings of $0.91 per share, reflecting a year-over-year decline of 18% [9]

Revenue Growth - Total revenue increased by 31% year-over-year to $18.9 million, driven primarily by strong software growth[1] - Software revenue grew by 41% to $10.7 million, representing 57% of total revenue, while services revenue increased by 19% to $8.2 million, accounting for 43% of total revenue[6] - The company expects fiscal 2025 revenue guidance to be between $90 million and $93 million, with a revenue growth rate of 28% to 33%[5] - Total revenue for FY24 reached $70.013 million, with Q1 revenue at $14.500 million and Q4 revenue at $18.664 million, showing a steady growth throughout the year[23] - Software revenue accounted for $41.024 million in FY24, with Q2 showing the highest quarterly revenue of $11.614 million[23] - The Americas region generated $50.473 million in revenue for FY24, accounting for the majority of total revenue[23] Profitability - The company achieved a gross profit of $10.2 million, resulting in a gross margin of 54%[6] - Net income for the quarter was $0.2 million, with diluted EPS of $0.01, compared to net income of $1.9 million and diluted EPS of $0.10 in the same quarter last year[6] - Adjusted EBITDA was $4.5 million, representing 24% of total revenue, compared to $3.4 million or 23% of total revenue in the prior year[6] - Adjusted EBITDA for FY24 was $20.257 million, with Q2 contributing $7.135 million, indicating strong operational performance[25] - Net income for FY24 totaled $9.954 million, with Q2 net income at $4.029 million, reflecting a significant increase compared to other quarters[27] - Adjusted diluted EPS for FY24 was $0.95, with Q2 adjusted diluted EPS at $0.32, reflecting improved profitability[27] Operational Performance - The gross margin for total revenue in FY24 was 61.6%, with software gross margin at 84.2% and services gross margin at 29.7%[23] - Cash flow from operations for FY24 was $13.320 million, with Q2 cash flow at $5.810 million, indicating strong liquidity[23] - The backlog for services stood at $17.254 million in Q1 FY25, showing a healthy pipeline for future revenue[23] Business Unit Performance - MonolixSuite™ contributed significantly with a growth rate of 43%, and the Quantitative Systems Pharmacology (QSP) business unit saw a 40% growth due to strong demand in specific disease areas[3] - Services revenue faced temporary headwinds due to client-driven data delays, but bookings were strong in Clinical Pharmacology & Pharmacometrics and Medical Communications[4] - The integration of Adaptive Learning and Insights (ALI) and Medical Communications (MC) business units is progressing well, with expectations for stronger momentum in the latter half of fiscal 2025[5] Customer Metrics - The average revenue per customer in the commercial segment was $94.0 thousand in Q1 FY25, demonstrating an increase from previous quarters[23]

Simulations Plus, Inc (SLP) is slated to release first-quarter fiscal 2025 results on Jan. 7.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $18.7 million, which indicates growth of 28.9% from the year-ago quarter’s reported figure.The consensus mark for earnings is pegged at 18 cents per share, indicating increase of 80% from the prior-year levels. The company’s earnings have surpassed the Zacks Consensus ...

Simulations Plus (SLP) closed the last trading session at $32.74, gaining 6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $51.40 indicates a 57% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $9.76. While the lowest estimate of $39 indicates a 19.1% increase from the current price level, the most optimistic analyst expects ...

Core Viewpoint - Simulations Plus (SLP) experienced an 8.9% increase in share price, closing at $30.04, following a significant volume of trading, contrasting with an 18.8% decline over the previous four weeks [1] Financial Performance - The increase in share price is attributed to strong topline performance driven by synergies from acquisitions and organic growth, with new customer acquisitions and increased sales in the Software segment contributing positively [2] - In the last reported quarter, the company achieved an organic revenue growth of 14%, excluding a $2.3 million contribution from the Pro-ficiency acquisition [3] Revenue Projections - For fiscal 2025, Simulations Plus anticipates revenues between $90 million and $93 million, indicating a growth of 28-33% from fiscal 2024 revenues, with organic growth projected between 10% and 15% [4] - The Pro-ficiency acquisition is expected to add an additional $15 million to $18 million to revenues, enhancing the financial outlook [4] Grants and Collaborations - Simulations Plus secured a grant from the U.S. Food and Drug Administration to support the use of its GastroPlus software in pharmacokinetic modeling, in collaboration with the University of Connecticut's School of Pharmacy [5] Earnings Expectations - The company is projected to report quarterly earnings of $0.18 per share, reflecting an 80% year-over-year increase, with revenues expected to reach $18.69 million, up 28.9% from the previous year [6] - The consensus EPS estimate for the quarter has been revised 105.9% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [7] Industry Context - Simulations Plus operates within the Zacks Computer - Software industry, where Autodesk (ADSK) also resides, having closed 2.5% higher recently and showing a 7.5% return over the past month [7]

Shares of Simulations Plus (SLP) have gained 1.1% over the past four weeks to close the last trading session at $30.70, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $54.50 indicates a potential upside of 77.5%.The average comprises four short-term price targets ranging from a low of $47 to a high of $65, with a standard deviation of $7.94. While the lowest estimate indicates ...

Simulations Plus, Inc. (SLP) reported fourth-quarter fiscal 2024 adjusted earnings (excluding the impact of acquisition costs) of 6 cents per share, which declined 66.7% year over year. The figure, however, beat the Zacks Consensus Estimate of 4 cents per share.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Quarterly revenues jumped 19% year over year to $18.7 million due to higher software and services revenues in the Clinical Pharmacology & Pharmacometrics (CPP), higher software ...

Simulations Plus (SLP) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 50%. A quarter ago, it was expected that this maker of software used in pharmaceutical research would post earnings of $0.16 per share when it actually produced earnings of $0.19, delivering a surprise of 18.75%.Ov ...

Exhibit 99.1 S+ SimulationsPlus Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Results Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 LANCASTER, CA, October 23, 2024 – Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelli ...